Iron chelation therapy for patients with sickle cell disease and iron overload

Authors

  • Adlette Inati,

    Corresponding author
    1. Division of Pediatric Hematology and Oncology, Children's Centre for Cancer and Blood Diseases, Rafik Hariri University Hospital, Beirut, Lebanon
    • Division of Pediatric Hematology-Oncology, Rafik Hariri University Hospital, Beirut; Founding Faculty, School of Medicine, Lebanese American University, Byblos and Beirut, Consultant Hematologist, Chronic Care Centre, Beirut, Lebanon
    Search for more papers by this author
  • Evelyne Khoriaty,

    1. Faculty of Medicine, American University of Beirut, Beirut, Lebanon
    Search for more papers by this author
  • Khaled M. Musallam,

    1. Department of Internal Medicine, Division of Hematology and Oncology, American University of Beirut Medical Centre, Beirut, Lebanon
    Search for more papers by this author
  • Ali T. Taher

    1. Department of Internal Medicine, Division of Hematology and Oncology, American University of Beirut Medical Centre, Beirut, Lebanon
    Search for more papers by this author

  • Conflict of interest: Adlette Inati and Ali T. Taher report receiving research funding from Novartis and involvement in the Novartis Speakers Bureau. Evelyne Khoriaty and Khaled M. Musallam have nothing to disclose.

  • A physician or group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.

Ancillary